New pill aims to shrink hepatitis b in HIV patients – early trial shows promise
NCT ID NCT05551273
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tested an oral drug called selgantolimod in 29 adults who have both chronic hepatitis B and HIV and have been on stable antiviral therapy for at least 5 years. The goal was to see if the drug is safe and can lower hepatitis B surface antigen (HBsAg) levels in the blood. Participants took the drug for 24 weeks while continuing their regular HIV and hepatitis B medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Barranco CRS
Lima, 04, Peru
-
Case CRS Site ID# 2501
Cleveland, Ohio, 44106, United States
-
Chapel Hill CRS
Chapel Hill, North Carolina, 27599, United States
-
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
Chiang Mai, 50200, Thailand
-
Cincinnati Children's Hosp / Univ Hosp
Cincinnati, Ohio, 452292899, United States
-
Columbia P&S CRS
New York, New York, 10032-3732, United States
-
De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC)
Cavite, 4114, Philippines
-
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, HT-6110, Haiti
-
Greensboro CRS Site# 3203
Greensboro, North Carolina, 27401, United States
-
Hospital Nossa Senhora da Conceicao CRS
Porto Alegre, 91350-200, Brazil
-
Houston AIDS Research Team CRS
Houston, Texas, 77030, United States
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, 21040-360, Brazil
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS Site ID# 12101
Rio de Janeiro, 21040-360, Brazil
-
Milton Park CRS
Milton Park, Harare, Zimbabwe
-
Northwestern University CRS
Chicago, Illinois, 60611, United States
-
Ohio State University CRS
Columbus, Ohio, 43210, United States
-
Soweto ACTG CRS
Johannesburg, Gauteng, 1862, South Africa
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Pathum Wan, Bangkok, 10330, Thailand
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308, United States
-
UCSD Antiviral Research Center CRS
San Diego, California, 92103, United States
-
Univ of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
University of Washington AIDS CRS
Seattle, Washington, 98104-9929, United States
-
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, 37204, United States
-
Weill Cornell Chelsea CRS
New York, New York, 10011, United States
-
Weill Cornell Uptown CRS
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.